Definitive Contract 75N91019C00032

Award Date 9/9/19
Potential Completion Date 3/15/22
Potential Value $2M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
30
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Diagnologix, LLC, a self-certified small disadvantaged business, for the development of "SBIR 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER." The firm-fixed-price contract, with a potential value of $350,000.00, has a completion date of August 31, 2018. This SBIR...
<p>This is a $1,999,984.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Diacarta, Inc. The contract is for the TOPIC 345 - SBIR PHASE II: RADTOX - MEASURING RADIATION TOXICITY USING CIRCULATING DNA project, which aims to develop a method for measuring radiation toxicity using circulating DNA. The contract has a Firm Fixed Price pricing type and is set to be completed by March 15, 2023.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Nvigen, Inc., a small disadvantaged business and woman-owned manufacturer. The contract is for the development of cell-free tumor DNA (ctDNA) diagnostic enabled by magnetic automation assays, under SBIR Topic 353. The contract has a firm fixed price of $275,261.00 and a completion date of August 18, 2017. The contract does not utilize a set-aside...
This is a firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to Digital Artefacts LLC, a minority-owned, small disadvantaged business. The contract is for the development of a &quot;CANCER PATIENT COGNITIVE ASSESSMENT PLATFORM&quot; under TOPIC 343, with a ceiling value of $216,431.00 and a completion date of September 18, 2017. The contract does not have a set-aside designation. As the NCI is the funding agency, this contract supports the...
This definitive firm fixed price contract was awarded by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services, to Digital Nanogenetics LLC on September 17, 2018. With a potential value of $300,000, the contract is associated with the Small Business Innovation Research Program Phase I and has a completion date of September 19, 2019. The contract has a set aside designation for total small businesses and will support research...
<p>The U.S. National Cancer Institute awarded a $395,448.37 firm fixed-price purchase order contract to Menarini Silicon Biosystems, Inc. for the procurement of one single cell isolation DEPArray system with 1-year dedicated, on-site field application support. The contract does not have a set-aside designation. The award is not associated with a larger contract vehicle. The contract was awarded on July 1, 2015 and has an ultimate completion date of April 18, 2020.</p>
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute (NCI) to Inlighta Biosciences L.L.C., a woman-owned small business. The $298,230.00 firm fixed-price contract is for a Phase I Small Business Innovation Research (SBIR) project titled &quot;Non-Invasive Subtyping of Aggressive Tumor and Its Environment&quot; as part of the NCI Cancer Moonshot initiative. The original solicitation was issued under the NIH/CDC...
This definitive firm fixed price contract from the Department of Health and Human Services National Institutes of Health National Cancer Institute, with a total small business set aside, is for $299,726.89 to Imago Systems Inc. for the development of a novel diagnostic imaging modality for monitoring tumor responses to a hyperthermia immunotherapy as part of the National Cancer Institute's Moonshot initiative. The award stems from Topic 375 of the NIH/CDC SBIR Contract Solicitation PHS 2018-1,...
This is a firm fixed-price purchase order awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The contract, valued at $95,509.00, is for the procurement of one (1) I-DOT 2.0 dispensing system for the preparation of next-generation sequencing (NGS) library preps of T-cell receptors (TCRs) in support of cancer research. The contract was set aside for small businesses, and the prime...
This is a $1,997,803 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to Cell Microsystems Inc., a small business manufacturer of specialized biomedical research equipment and tools. The contract is for the topic &quot;Integrated Imaging and Molecular Analysis of Glioblastoma Using SCOPE SEQ on the Air Flow&quot; and has a total small business set-aside designation. The contract will support...

The National Cancer Institute awarded a $2,000,000.00 firm fixed price definitive contract to Diagnologix, LLC, a small disadvantaged business, for the development of a "TOPIC 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER- MOONSHOT" project. The contract has an ultimate completion date of March 15, 2022 and was awarded on September 9, 2019. No set-aside designation was used for this contract.

Generated 9/4/24, 9:06 AM